BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 517 filers reported holding BIO-TECHNE CORP in Q3 2023. The put-call ratio across all filers is 0.43 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $543,248 | +2.2% | 6,655 | -7.1% | 0.05% | +47.1% |
| Q1 2023 | $531,497 | -10.5% | 7,164 | -0.0% | 0.03% | -42.4% |
| Q4 2022 | $593,835 | -54.3% | 7,165 | +56.6% | 0.06% | +18.0% |
| Q3 2022 | $1,299,000 | +328.7% | 4,574 | +380.0% | 0.05% | -19.4% |
| Q4 2020 | $303,000 | +18.8% | 953 | -7.5% | 0.06% | +1.6% |
| Q3 2020 | $255,000 | -14.4% | 1,030 | -8.8% | 0.06% | -20.8% |
| Q2 2020 | $298,000 | +34.8% | 1,130 | -3.3% | 0.08% | +2.7% |
| Q1 2020 | $221,000 | -26.3% | 1,168 | -14.7% | 0.08% | -3.8% |
| Q4 2019 | $300,000 | +7.9% | 1,370 | -3.5% | 0.08% | -2.5% |
| Q3 2019 | $278,000 | -5.8% | 1,420 | +0.1% | 0.08% | -15.8% |
| Q2 2019 | $295,000 | -9.5% | 1,419 | -13.6% | 0.10% | -10.4% |
| Q1 2019 | $326,000 | +169.4% | 1,642 | +95.0% | 0.11% | +103.8% |
| Q4 2018 | $121,000 | -13.6% | 842 | -8.9% | 0.05% | -18.8% |
| Q1 2018 | $140,000 | +300.0% | 924 | +241.0% | 0.06% | +300.0% |
| Q4 2017 | $35,000 | – | 271 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadcrest Asset Management, LLC | 275,000 | $18,719,250 | 20.14% |
| Montanaro Asset Management Ltd | 408,800 | $27,827,016 | 4.90% |
| Sandhill Capital Partners LLC | 613,061 | $41,731,091 | 3.90% |
| Pembroke Management, LTD | 365,611 | $24,887,141 | 3.40% |
| DF DENT & CO INC | 3,349,047 | $227,969,648 | 3.34% |
| Brown Capital Management | 3,158,004 | $214,965,332 | 3.30% |
| Ownership Capital B.V. | 1,786,273 | $121,591,603 | 3.05% |
| STONE RUN CAPITAL, LLC | 86,335 | $5,876,823 | 2.88% |
| Jackson Square Partners, LLC | 1,260,547 | $85,805,434 | 2.87% |
| Summit Creek Advisors LLC | 284,681 | $19,378,236 | 2.64% |